4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
US-10206913-B2 · Feb 19, 2019 · US
4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
US10441579B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10441579-B2 |
| Application number | US-201916239265-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 3, 2019 |
| Priority date | Nov 14, 2008 |
| Publication date | Oct 15, 2019 |
| Grant date | Oct 15, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to compounds of formula I: where a, R 1 , and R 3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
First claim
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition comprising: (a) a compound of the formula: or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier selected from starch, microcrystalline cellulose, lactose, sucrose, glucose, mannitol, silicic acid and mixtures thereof. 2. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable carrier is microcrystalline cellulose. 3. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable carrier is lactose. 4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises a lubricant selected from talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate and mixtures thereof. 5. The pharmaceutical composition of claim 4 , wherein the lubricant is magnesium stearate. 6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition contains about 1 milligram to about 20 milligrams of the compound or a pharmaceutically acceptable salt thereof. 7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition contains about 1 milligram to about 15 milligrams of the compound or a pharmaceutically acceptable salt thereof. 8. The pharmaceutical composition of claim 1 wherein the pharmaceutical composition contains about 1 milligram to about 10 milligrams of the compound or a pharmaceutically acceptable salt thereof. 9. The pharmaceutical composition of any one of claims 1 - 8 , wherein the compound is a hydrochloride salt.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
for treating abuse or dependence · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10441579B2 cover?
- The invention relates to compounds of formula I: where a, R 1 , and R 3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process …
- Who is the assignee on this patent?
- Theravance Biopharma R&D Ip Llc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4465. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).